Flow Cytometry in the Management of Breast Cancer
There is a pressing need for the further definition of prognostic factors capable of defining the clinical course of patients with primary breast cancer. Current data suggest that approximately 50% of women will present with node-negative (N -) disease, 35% with node-positive (N + ) disease, and 15% with metastases . Of these patients, 25% with N - and 60% with N + will develop locally recurrent or metastatic disease over a 10-year follow-up period. Adjuvant chemotherapy and/or endocrine therapy following primary treatment provides potentially curative treatment for an additional 10%–25% of patients with N+ disease, and current trials suggest benefit in N- patients . For patients with primary operable breast cancer, a continuing clinical dilemma related to the use of adjuvant therapy is the need to treat all patients of a given stage in order to provide effective treatment for only a small proportion of the population. Although tumor size, histologic grade, and steroid receptor status provide information suggesting recurrence risk for large groups of patients, there remains no satisfactory tool for accurate prediction of recurrence in the individual.
KeywordsBreast Cancer Primary Breast Cancer Steroid Receptor High Proliferative Index Ploidy Status
Unable to display preview. Download preview PDF.
- 1.Adami HO, Killander D (1984) Prediction of survival in breast cancer - a review. Acta Chir Scand 519: 25–34Google Scholar
- 3.Azzopardi JP, Chepick OF, Hartmann WH, Jafarey NA, Llombart-Bosch A, Ozzello L, Rilke F, Sassano N, Sobin LH, Sommers SC, Stalsberg H, Sugar J, Williams HO (1982) The World Health Organization histological typing of breast tumors - second edition. Am J Clin Pathol 78: 806–816Google Scholar
- 6.Cornelisse CJ, Moolenaar AJ, Kooyman HJ (1985) Aneuploidy and survival in 566 breast cancer cases. International Conference on Analytical Cytometry XI. Hilton Head, SC, Abst. 340Google Scholar
- 8.Cox DR: (1972) Regression models and life tables (with discussion). J R Stat Soc B 34: 187–220Google Scholar
- 10.Dressier L, Clark G, Owens M, Pounds G, Oldaker T, McGuire W (1987) DNA flow cytometry predicts for relapse in node negative breast cancer patients. Proc Am Soc Clin Oncol 6:57 (Abst)Google Scholar
- 21.Klintenberg C, Stal O, Nordenskjold B, Wallgren A, Arvidsson S, Skoog L (1986) Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat (Suppl) 7: 99–106Google Scholar
- 32.Muss HB (1984) Principles of cancer chemotherapy; In: Deppe G (ed) Chemotherapy of gynecologic malignancy. Liss, New York, pp 1–30Google Scholar
- 35.Proceedings of the NIH development conference on adjuvant chemotherapy and endocrine therapy for breast cancer. (1986) NCI Monogr 1:1–4Google Scholar
- 36.Retsky MW, Swartzendruber DE, Wardell RH: (1985) Predicting the disease free survival of breast cancer patients using DNA index and a stochastic numerical model of breast cancer growth. International Conference on Analytical Cytometry XI. Hilton Head, SC, abst 343Google Scholar